CASI PHARMACEUTICALS, INC.: 10-Q filed 2013-05-15
What CASI PHARMACEUTICALS, INC. reported in its quarterly report filed 2013-05-15 (fiscal Q1 2013): 26 published measures, 54 facts as tagged in accession 0001144204-13-029049.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-05-15
- Fiscal period
- fiscal Q1 2013
- Accession
- 0001144204-13-029049 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CASI PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 18,487,373 | USD | |
| At 2012-12-31 | 8,977,995 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 17,692,798 | USD | |
| At 2012-12-31 | 8,235,242 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 18,270,729 | USD | |
| At 2012-12-31 | 8,049,237 | USD | |
| At 2012-03-31 | 11,345,510 | USD | |
| At 2011-12-31 | 1,080,630 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -1,135,887 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -2,533,858 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -139,901 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 946,836 | USD | 91 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 13,147 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 0 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 10,374,540 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 9,318,044 | USD | 91 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -13,147 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 0 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | -394,467,134 | USD | |
| At 2012-12-31 | -393,331,247 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 61,040 | USD | |
| At 2012-12-31 | 52,556 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 218,903 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 264,222 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 18,408,906 | USD | |
| At 2012-12-31 | 8,908,012 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -390 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 875,863 | USD | 91 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 794,575 | USD | |
| At 2012-12-31 | 742,753 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 648,895 | USD | |
| At 2012-12-31 | 504,851 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 0 | USD | |
| At 2012-12-31 | 669,310 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 506,375 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 561,249 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 27,102,583 | shares | |
| At 2012-12-31 | 22,582,938 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 419,923,152 | USD | |
| At 2012-12-31 | 409,374,905 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 17,427 | USD | |
| At 2012-12-31 | 17,427 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 145,680 | USD | |
| At 2012-12-31 | 151,219 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-03-31 | 138,177 | USD | |
| At 2012-12-31 | 189,465 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -1,135,887 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -2,785,108 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 629,902 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 1,096,746 | USD | 91 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | -669,310 | USD | 90 |
| 2012-01-01 to 2012-03-31 | -1,932,742 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-03-31 | 144,044 | USD | 90 |
| 2012-01-01 to 2012-03-31 | 290,550 | USD | 91 |
Inspect the source
- Entity
- CASI PHARMACEUTICALS, INC. / CIK 0000895051
- Captured
- SEC response SHA-256
a5465bb63979ec441cdd2d0b7761265dc0541f5ee25dcdffded348a960f99c09
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000895051.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))